Surmodics Inc. (SRDX) and Its Competitors Comparing side by side. – MS Wkly

Posted: Published on October 17th, 2019

This post was added by Alex Diaz-Granados

As Diagnostic Substances company, Surmodics Inc. (NASDAQ:SRDX) is competing with its competitors based on the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Institutional & Insider Ownership

87.8% of Surmodics Inc.s shares are owned by institutional investors. Comparatively, 68.89% of all Diagnostic Substancess companies shares are owned by institutional investors. On other hand Surmodics Inc. has 2.6% of its shares owned by company insiders vs. an average of 3.74% insiders ownership for its competitors.

Profitability

Table 1 has Surmodics Inc. and its competitors return on equity, return on assets and net margins.

Earnings & Valuation

The following data compares Surmodics Inc. and its competitors top-line revenue, net income and valuation.

Analyst Recommendations

Table 3 provides breakdown of current ratings for Surmodics Inc. and its competitors.

The competitors have a potential upside of 248.42%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Surmodics Inc. and its competitors.

For the past year Surmodics Inc. had bearish trend while Surmodics Inc.s competitors had bullish trend.

Liquidity

Surmodics Inc. has a Current Ratio of 3.5 and a Quick Ratio of 3.3. Competitively, Surmodics Inc.s competitors Current Ratio is 5.13 and has 4.28 Quick Ratio. Surmodics Inc.s competitors have better ability to pay short and long-term obligations than Surmodics Inc.

Volatility & Risk

A beta of 1.16 shows that Surmodics Inc. is 16.00% more volatile than Standard & Poors 500. In other hand, Surmodics Inc.s competitors have beta of 1.28 which is 27.91% more volatile than Standard & Poors 500.

Dividends

Surmodics Inc. does not pay a dividend.

Summary

Surmodics Inc.s competitors show that theyre better in 4 of the 4 factors compared to the company itself.

Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. This segment also engages in the contract research, development, and manufacture of percutaneous transluminal angioplasty balloon catheters for use in various interventional cardiology, peripheral, and other applications. The Vitro Diagnostics segment provides component products and technologies that include protein stabilization reagents, substrates, antigens, and surface coatings for diagnostic immunoassay and molecular tests, as well as to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more here:

Surmodics Inc. (SRDX) and Its Competitors Comparing side by side. - MS Wkly

Related Posts
This entry was posted in Interventional Cardiology. Bookmark the permalink.

Comments are closed.